1 PhD position in Molecular Neuroscience in Erlangen
We are looking for a highly motivated student with strong background in molecular and cellular neuroscience or related field interested in epigenetic control of adult neurogenesis and role of this process in human depression.
The lab is interested in molecular and cellular mechanisms that control plasticity of neurotransmitter release and presynapse-to-nucleus signalling and their role in normal brain function and in disease (Davydova et al., Neuron 2014; Ivanova et al., EMBO J 2015; Altmüller et al., PLoS Genetics 2017; Lazarevic et al., Front Mol Neurosci 2017 and Neuropharmacology 2018, Heck et al., Neuron, 2019 ). For our research, we use a broad spectrum of methods ranging from biochemical and molecular techniques, mouse genetics, behavioural analysis, -omics approaches, neurophysiology, and super-resolution and live imaging in neurons.
We offer a 3-year PhD program with interdisciplinary thesis research with structured supervision and mentorship, a vibrant, collaborative scientific environment, advanced training opportunities in English covering scientific, skills and career-development topics. For details see: http://www.grk2162.med.fau.de
You are highly motivated, with excellent M.Sc. or equivalent degree in neurobiology, biochemistry or related areas. A previous experience in field of cellular or molecular neuroscience is an advantage. A strong dedication to basic and translational neuroscience, willingness to contribute to the development of your PhD project by own ideas and readiness to take over responsibilities within an interdisciplinary team are absolute must.
Please, submit your application containing letter of motivation, CV, transcript of records, summary of research experience and master project and two names of faculty members that agreed to support your application by a letter of a reference as single PDF file to: Anna.Fejtova@uk-erlangen.de (Subject: PhD position- Your name). Application closing date: 15th July 2019
Start date August/September 2019 or upon agreement.
Prof. Anna Fejtova
Division of Molecular Psychiatry
Department of Psychiatry and Psychotherapy
University Hospital Erlangen